Compositions and methods for treating glioblastoma GBM
AssigneeVascular Biogenics Ltd.
InventorsYael Cohen, Livnat Bangio, Andrew J. Brenner, Eyal Breitbart
Life of this patent
Estimating the term…
Abstract
Methods of treating a malignant glioma in a subject are disclosed. The methods comprise administering to the subject a therapeutically effective amount of a viral vector comprising: (i) a first polynucleotide sequence encoding a Fas-chimera (Fas-c), said first polynucleotide sequence comprising SEQ ID NOs: 2 and 3; and (ii) a second polynucleotide sequence encoding an endothelial cell-specific promoter or a periendothelial cell-specific promoter.
Claims17
A method of treating a malignant glioma in a subject in need thereof, the method comprising administering directly into the malignant glioma or intravenously to the subject a therapeutically effective amount of a non-replicating adenovirus serotype 5 vector (Ad5), wherein said adenoviral vector comprises:
- (i) a first nucleotide sequence comprising the nucleotide sequence of the extracellular region of TNFR1 as set forth in SEQ ID NO:2 fused to the trans-membrane and intracellular regions of Fas as set forth in SEQ ID NO:3 encoding a Fas-chimera (Fas-c);
- and
- (ii) a second nucleotide sequence of an endothelial cell-specific promoter comprising the nucleotide sequence as set forth in SEQ ID NO:6, or the complementary sequence thereof,
- wherein said second nucleotide sequence is operably linked to and is upstream of said first nucleotide sequence for expression of said Fas-chimera in endothelial cells, and
- wherein growth of the malignant glioma is inhibited.
Dependencies are inferred from the claim text.